Transcatheter aortic valve implantation with either CoreValve or SAPIEN XT devices in patients with a single coronary artery.
Transcatheter aortic valve implantation (TAVI) is associated with a risk of coronary obstruction. This complication is potentially lethal when the origin of the coronary arteries is anomalous. We describe two cases of TAVI with the SAPIEN XT (Edwards Lifesciences) and CoreValve devices (Medtronic) in patients with a single coronary artery. The tools and techniques used to anticipate the risk of acute coronary occlusion are discussed.
Clinique Pasteur, Groupe CardioVasculaire Interventionnel, 45 avenue de Lombez, 31300, Toulouse, France.
Emmanuel
E
Sorbets
Michael
M
Choby
Didier
D
Tchetche
D000369:Aged, 80 and over; D001021:Aortic Valve / Q000601:surgery*; D001024:Aortic Valve Stenosis / Q000601:surgery*; D062906:Cardiac Catheters; D017023:Coronary Angiography; D054059:Coronary Occlusion / Q000453:epidemiology*; D003330:Coronary Vessel Anomalies / Q000150:complications* / Q000000981:diagnostic imaging; D005260:Female; D006350:Heart Valve Prosthesis / Q000009:adverse effects / Q000145:classification*; D006801:Humans; D019919:Prosthesis Implantation / Q000009:adverse effects / Q000295:instrumentation / Q000379:methods*; D012307:Risk Factors; D012850:Sinus of Valsalva / Q000002:abnormalities; D016896:Treatment Outcome